var data={"title":"Invasive Malassezia infections","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Invasive Malassezia infections</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/contributors\" class=\"contributor contributor_credentials\">Denis Spelman, MBBS, FRACP, FRCPA, MPH</a></dd><dd><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/contributors\" class=\"contributor contributor_credentials\">CO Morrissey, MB, BCh, FRACP, Grad Dip (Clin Epi), PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 02, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Malassezia</em> (formerly known as <em>Pityrosporum</em>) species are members of human cutaneous commensal flora, which are associated with a wide spectrum of clinical manifestations from benign skin conditions, such as tinea versicolor and folliculitis, to fungemia in the immunocompromised host [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/1-4\" class=\"abstract_t\">1-4</a>].</p><p>The epidemiology, clinical manifestations, diagnosis, and treatment of invasive <em>Malassezia </em>infections will be discussed here. The clinical manifestations, diagnosis, and treatment of tinea versicolor and <em>Malassezia</em> folliculitis are discussed elsewhere. (See <a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">&quot;Tinea versicolor (Pityriasis versicolor)&quot;</a> and <a href=\"topic.htm?path=infectious-folliculitis#H604478886\" class=\"medical medical_review\">&quot;Infectious folliculitis&quot;, section on 'Fungal folliculitis'</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MYCOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Malassezia</em> are lipophilic yeasts that are constituents of the normal human skin flora. These organisms have been classified into at least 14 species, including <em>M. furfur</em>, <em>M. pachydermatis</em>, <em>M. sympodialis</em>, <em>M. slooffiae</em>, <em>M. obtusa</em>, <em>M. globosa</em>, and <em>M. restricta</em>, based upon polymerase chain reaction and restriction endonuclease analysis [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/2,5-8\" class=\"abstract_t\">2,5-8</a>]. A study has reported reliable species identification by matrix-assisted laser <span class=\"nowrap\">desorption/ionization</span> time-of-flight (MALDI-TOF) mass spectrometry following the development of a MALDI-TOF database [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Malassezia</em> species mainly colonize the skin and occasionally the respiratory tract [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/7,10\" class=\"abstract_t\">7,10</a>]. The organisms appear to become part of the normal skin flora by three to six months of age. <em>M. furfur</em> was recovered from the skin in 32 to 64 percent of neonates in neonatal intensive care units in two separate series [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In one study, duration of stay in the unit and gestational age were factors favoring skin colonization [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Colonization of the skin with <em>Malassezia</em> and subsequent extension to central venous catheters appears more common in neonates than adults. Studies using scanning electron microscopy have demonstrated that some <em>Malassezia</em> spp produce significant biofilms [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/13\" class=\"abstract_t\">13</a>]. <em>M. furfur</em> was recovered from the lumen in 32 percent of percutaneous central venous catheters in a neonatal intensive care unit in one series [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/12\" class=\"abstract_t\">12</a>] but not from the insertion sites in 928 adults receiving <a href=\"topic.htm?path=total-parenteral-nutrition-drug-information\" class=\"drug drug_general\">total parenteral nutrition</a> [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/14\" class=\"abstract_t\">14</a>].</p><p>This fact may account for the observation that <em>Malassezia </em>central venous<em> </em>catheter&ndash;related infections are more common in preterm neonates than adults. High temperature and humidity may facilitate colonization of catheters, and lipid infusions appear to predispose to both catheter colonization and infections [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/15-17\" class=\"abstract_t\">15-17</a>]. Additional risk factors for <em>Malassezia</em> catheter-related infections in newborns include low birthweight, severe comorbidities, and arterial catheterization for longer than nine days [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/18\" class=\"abstract_t\">18</a>].</p><p>Both localized skin and mucosal infections and systemic infections have been reported in hematopoietic cell transplant recipients [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>], patients with underlying hematologic malignancies, those receiving monoclonal antibody therapy for cancer [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/20\" class=\"abstract_t\">20</a>], and in patients with other immunodeficiency states (eg, solid organ transplantation, diabetes mellitus, prolonged glucocorticoid therapy) [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/21\" class=\"abstract_t\">21</a>]. Unlike many of the other more common opportunistic fungal infections in immunocompromised patients, neutropenia and the use of broad-spectrum antimicrobials do not appear to be significant risk factors for <em>Malassezia</em> infections in hematopoietic cell transplant recipients [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>]. In addition, despite the presence of fungemia, disseminated fungal infection is uncommon.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Outbreaks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hospital outbreaks of <em>Malassezia </em>infection have been described [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/17,18,22\" class=\"abstract_t\">17,18,22</a>]. In one outbreak, there was simultaneous occurrence of <em>M. furfur</em> infection in three intensive care unit patients in neighboring beds [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/22\" class=\"abstract_t\">22</a>]. In a second outbreak, the organism was isolated from the hands of healthcare workers and the healthcare workers' pet dogs; all isolates had an identical pattern of restriction fragment length polymorphisms [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/18\" class=\"abstract_t\">18</a>]. An outbreak in a neonatal intensive care unit, which was caused by multiple <em>Malassezia</em> genotypes, has also been described [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/23\" class=\"abstract_t\">23</a>]. Although a source was not identified, effective infection prevention methods included removal of a lipid-rich moisturizing hand cream used by staff.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Malassezia</em> infections can be localized <span class=\"nowrap\">and/or</span> systemic in immunocompromised hosts. <em>Malassezia </em>spp<em> </em>can produce the following clinical syndromes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Malassezia</em> folliculitis presents with pruritic, monomorphic, follicular papules or pustules on the chest, back, <span class=\"nowrap\">and/or</span> shoulders. Less frequent sites of involvement include the face, neck, and extensor side of the arms. (See <a href=\"topic.htm?path=infectious-folliculitis#H604478886\" class=\"medical medical_review\">&quot;Infectious folliculitis&quot;, section on 'Fungal folliculitis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Catheter-related fungemia, especially in preterm neonates receiving lipid infusions (ie, <a href=\"topic.htm?path=total-parenteral-nutrition-drug-information\" class=\"drug drug_general\">total parenteral nutrition</a>) through a central venous catheter [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/17\" class=\"abstract_t\">17</a>] &ndash; The clinical examination, apart from fever, may be unremarkable [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>]. Septic thrombosis of the superior vena cava [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/24\" class=\"abstract_t\">24</a>] and peripheral thromboembolism [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/25\" class=\"abstract_t\">25</a>] have been described.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Localized infections, including meningitis and urinary tract infections have been described [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/18\" class=\"abstract_t\">18</a>]. Rarely, <em>Malassezia</em> species have been implicated in cases of peritonitis, mastitis, septic arthritis, and sinusitis [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/21,26\" class=\"abstract_t\">21,26</a>].</p><p/><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with fungemia, meningitis, peritonitis, or septic arthritis, a definitive diagnosis is made by detection of characteristic yeasts on histologic or cytologic examination of a biopsy or needle aspirate specimen or positive culture from a sterile site (<a href=\"image.htm?imageKey=ID%2F71053\" class=\"graphic graphic_picture graphicRef71053 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/27\" class=\"abstract_t\">27</a>]. The culture of <em>Malassezia</em> spp from urine in the absence of a urinary catheter or from a sinus aspirate is diagnostic of <em>Malassezia</em> urinary tract infection or sinusitis, respectively.</p><p><em>Malassezia</em> require fatty acids for growth and, thus, do not grow on routine laboratory media. On microscopy, <em>Malassezia</em> have characteristic features. The yeast is typically thick walled (3 to 8 mcg in diameter), round to oval in shape, with a broad-based bud and collarette at one pole. Hyphae and pseudohyphae are rarely seen [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>]. If the diagnosis of <em>Malassezia</em> infection is suspected based on the morphologic findings, the specimen should be plated onto specialized media, such as Dixon agar, which contains glycerol mono-oleate, or Sabouraud dextrose agar, covered with a layer of olive oil and incubated at 37&ordm;C [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/18,19,21,22,24,25,28,29\" class=\"abstract_t\">18,19,21,22,24,25,28,29</a>]. Identification is usually confirmed on the basis of microscopic appearance and the need for specialized media.</p><p>Newer methods of identification of <em>Malassezia</em> spp include matrix-assisted laser <span class=\"nowrap\">desorption/ionization</span> time-of-flight mass spectrometry (MALDI-TOF) [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/30\" class=\"abstract_t\">30</a>] and multiplex polymerase chain reaction (PCR) [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/31\" class=\"abstract_t\">31</a>]. These methods may be useful adjunctive tests for rapid identification, particularly in outbreak settings.</p><p>Serum (1,3)-beta-D-glucan was assessed for the diagnosis of invasive yeast infection in 47 neonates in a neonatal intensive care unit but does not appear to be positive in the setting of invasive <em>Malassezia</em> infection [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/32\" class=\"abstract_t\">32</a>].</p><p>The diagnosis of <em>Malassezia</em> folliculitis is discussed separately. (See <a href=\"topic.htm?path=infectious-folliculitis#H604478904\" class=\"medical medical_review\">&quot;Infectious folliculitis&quot;, section on 'Diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">SUSCEPTIBILITY TESTING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because <em>Malassezia</em> spp do not grow on the recommended susceptibility media, susceptibility testing has not been standardized for this organism [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/33\" class=\"abstract_t\">33</a>]. Reports have described experience with optimized broth microdilution and E-tests methodologies [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/34-36\" class=\"abstract_t\">34-36</a>]. In vitro, all <em>Malassezia</em> spp appear susceptible to amphotericin B (0.3 to 2.5 <span class=\"nowrap\">mcg/mL)</span> and azole agents, including <a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">ketoconazole</a>, <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> (0.016 to 0.25 <span class=\"nowrap\">mcg/mL),</span> and <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>. However, the minimal inhibitory concentrations (MIC) for <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> are somewhat higher (0.5 to 6.5 <span class=\"nowrap\">mcg/mL)</span> [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/37,38\" class=\"abstract_t\">37,38</a>]. <em>Malassezia </em>spp have variable susceptibility to <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a> with MICs that range from 0.06 <span class=\"nowrap\">mcg/mL</span> for <em>M. globosa</em> to 32 <span class=\"nowrap\">mcg/mL</span> for <em>M. furfur </em>[<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/37,38\" class=\"abstract_t\">37,38</a>]. Echinocandins and <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">griseofulvin</a> appear to have no activity against <em>Malassezia</em> spp [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/34,39\" class=\"abstract_t\">34,39</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Central venous catheter&ndash;related <em>Malassezia </em>infections are usually treated with catheter removal, discontinuation of the lipid infusion (ie, <a href=\"topic.htm?path=total-parenteral-nutrition-drug-information\" class=\"drug drug_general\">total parenteral nutrition</a>), and administration of antifungal therapy [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>]. However, there are reports of successful eradication of infection with antifungal therapy without catheter removal [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/21\" class=\"abstract_t\">21</a>] and with catheter removal without systemic antifungal treatment [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>].</p><p>For treatment of <em>Malassezia</em> infection, we use a lipid formulation of amphotericin B (3 to 5 <span class=\"nowrap\">mg/kg</span> intravenously [IV] daily). An exception is the rare occurrence of urinary tract infection for which we use <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (0.3 to 0.5 <span class=\"nowrap\">mg/kg</span> IV once daily) in adults because lipid formulations of amphotericin B do achieve adequate concentrations in the urine. (See <a href=\"topic.htm?path=candida-infections-of-the-bladder-and-kidneys#H15\" class=\"medical medical_review\">&quot;Candida infections of the bladder and kidneys&quot;, section on 'Fluconazole-resistant Candida'</a>.)</p><p>In neonates with <em>Malassezia</em> infection, <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (0.7 <span class=\"nowrap\">mg/kg</span> IV once daily) is used rather than a lipid formulation.</p><p>Therapy with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> is an alternative option, based on in vitro data rather than clinical studies. <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">Fluconazole</a> should not be used because its in vitro activity is inferior to the in vitro activity of the other azoles. There are no reports of treatment of <em>Malassezia</em> with echinocandins, most likely related to the lack of in vitro activity of this class of antifungal agents against <em>Malassezia</em> species. (See <a href=\"#H7\" class=\"local\">'Susceptibility testing'</a> above.)</p><p>The management of folliculitis caused by <em>Malassezia</em> spp is discussed separately. (See <a href=\"topic.htm?path=infectious-folliculitis#H604478916\" class=\"medical medical_review\">&quot;Infectious folliculitis&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">OUTCOME OF INFECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>With catheter removal and discontinuation of intravenous lipids (ie, <a href=\"topic.htm?path=total-parenteral-nutrition-drug-information\" class=\"drug drug_general\">total parenteral nutrition</a>), the outcome is usually favorable, even in transplant patients with fungemia [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"abstract_t\">19</a>].</p><p>In 11 cases of folliculitis occurring in heart transplant recipients, six responded to topical applications of <a href=\"topic.htm?path=clotrimazole-drug-information\" class=\"drug drug_general\">clotrimazole</a> (1 percent) and <a href=\"topic.htm?path=selenium-sulfide-drug-information\" class=\"drug drug_general\">selenium sulfide</a>, and the remainder responded to <a href=\"topic.htm?path=fluconazole-drug-information\" class=\"drug drug_general\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Malassezia</em> species are members of human cutaneous commensal flora, which are associated with intravascular catheter&ndash;related infections and folliculitis in the immunocompromised host. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Central venous catheter&ndash;related bloodstream infections are seen most commonly in premature neonates receiving lipid infusions (ie, <a href=\"topic.htm?path=total-parenteral-nutrition-drug-information\" class=\"drug drug_general\">total parenteral nutrition</a> [TPN]). Additional risk factors include low birthweight, severe comorbidities, and arterial catheterization for longer than nine days. (See <a href=\"#H3\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A definitive diagnosis is made by culture from a sterile site. If the diagnosis of <em>Malassezia</em> is being considered, Sabouraud dextrose agar must be plated at 37&ordm;C, and the specimen must be covered with a layer of olive oil. (See <a href=\"#H6\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend the administration of a lipid formulation of amphotericin B for treatment of central venous catheter&ndash;related <em>Malassezia </em>infections (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). Therapy with <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> is an alternative option. We also suggest central venous catheter removal and discontinuation of lipid infusions (ie, TPN) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H8\" class=\"local\">'Treatment'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/1\" class=\"nounderline abstract_t\">Crespo-Erchiga V, Florencio VD. Malassezia yeasts and pityriasis versicolor. Curr Opin Infect Dis 2006; 19:139.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/2\" class=\"nounderline abstract_t\">Ben Salah S, Makni F, Marrakchi S, et al. Identification of Malassezia species from Tunisian patients with pityriasis versicolor and normal subjects. Mycoses 2005; 48:242.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/3\" class=\"nounderline abstract_t\">Jahagirdar BN, Morrison VA. Emerging fungal pathogens in patients with hematologic malignancies and marrow/stem-cell transplant recipients. Semin Respir Infect 2002; 17:113.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/4\" class=\"nounderline abstract_t\">Ashbee HR, Evans EG. Immunology of diseases associated with Malassezia species. Clin Microbiol Rev 2002; 15:21.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/5\" class=\"nounderline abstract_t\">Gupta AK, Kohli Y, Faergemann J, Summerbell RC. Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada. Med Mycol 2001; 39:199.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/6\" class=\"nounderline abstract_t\">Gupta AK, Kohli Y, Summerbell RC. Molecular differentiation of seven Malassezia species. J Clin Microbiol 2000; 38:1869.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/7\" class=\"nounderline abstract_t\">Gaitanis G, Magiatis P, Hantschke M, et al. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25:106.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/8\" class=\"nounderline abstract_t\">Ilahi A, Hadrich I, Neji S, et al. Real-Time PCR Identification of Six Malassezia Species. Curr Microbiol 2017; 74:671.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/9\" class=\"nounderline abstract_t\">Denis J, Machouart M, Morio F, et al. Performance of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identifying Clinical Malassezia Isolates. J Clin Microbiol 2017; 55:90.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/10\" class=\"nounderline abstract_t\">Smolinski KN, Shah SS, Honig PJ, Yan AC. Neonatal cutaneous fungal infections. Curr Opin Pediatr 2005; 17:486.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/11\" class=\"nounderline abstract_t\">Ashbee HR, Leck AK, Puntis JW, et al. Skin colonization by Malassezia in neonates and infants. Infect Control Hosp Epidemiol 2002; 23:212.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/12\" class=\"nounderline abstract_t\">Aschner JL, Punsalang A Jr, Maniscalco WM, Menegus MA. Percutaneous central venous catheter colonization with Malassezia furfur: incidence and clinical significance. Pediatrics 1987; 80:535.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/13\" class=\"nounderline abstract_t\">Angiolella L, Leone C, Rojas F, et al. Biofilm, adherence, and hydrophobicity as virulence factors in Malassezia furfur. Med Mycol 2018; 56:110.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/14\" class=\"nounderline abstract_t\">Jatoi A, Hanjosten K, Ross E, Mason JB. A prospective survey for central line skin-site colonization by the pathogen Malassezia furfur among hospitalized adults receiving total parenteral nutrition. JPEN J Parenter Enteral Nutr 1997; 21:230.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/15\" class=\"nounderline abstract_t\">Gupta AK, Kohli Y, Li A, et al. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine. Br J Dermatol 2000; 142:758.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/16\" class=\"nounderline abstract_t\">Papavassilis C, Mach KK, Mayser PA. Medium-chain triglycerides inhibit growth of Malassezia: implications for prevention of systemic infection. Crit Care Med 1999; 27:1781.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/17\" class=\"nounderline abstract_t\">Chryssanthou E, Broberger U, Petrini B. Malassezia pachydermatis fungaemia in a neonatal intensive care unit. Acta Paediatr 2001; 90:323.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/18\" class=\"nounderline abstract_t\">Chang HJ, Miller HL, Watkins N, et al. An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs. N Engl J Med 1998; 338:706.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/19\" class=\"nounderline abstract_t\">Morrison VA, Weisdorf DJ. The spectrum of Malassezia infections in the bone marrow transplant population. Bone Marrow Transplant 2000; 26:645.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/20\" class=\"nounderline abstract_t\">Cholongitas E, Pipili C, Ioannidou D. Malassezia folliculitis presented as acneiform eruption after cetuximab administration. J Drugs Dermatol 2009; 8:274.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/21\" class=\"nounderline abstract_t\">Barber GR, Brown AE, Kiehn TE, et al. Catheter-related Malassezia furfur fungemia in immunocompromised patients. Am J Med 1993; 95:365.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/22\" class=\"nounderline abstract_t\">Archer-Dubon C, Icaza-Chivez ME, Orozco-Topete R, et al. An epidemic outbreak of Malassezia folliculitis in three adult patients in an intensive care unit: a previously unrecognized nosocomial infection. Int J Dermatol 1999; 38:453.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/23\" class=\"nounderline abstract_t\">Ilahi A, Hadrich I, Goudjil S, et al. Molecular epidemiology of a Malassezia pachydermatis neonatal unit outbreak. Med Mycol 2018; 56:69.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/24\" class=\"nounderline abstract_t\">Schleman KA, Tullis G, Blum R. Intracardiac mass complicating Malassezia furfur fungemia. Chest 2000; 118:1828.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/25\" class=\"nounderline abstract_t\">Kessler AT, Kourtis AP, Simon N. Peripheral thromboembolism associated with Malassezia furfur sepsis. Pediatr Infect Dis J 2002; 21:356.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/26\" class=\"nounderline abstract_t\">Gidding H, Hawes L, Dwyer B. The isolation of Malassezia furfur from an episode of peritonitis. Med J Aust 1989; 151:603.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/27\" class=\"nounderline abstract_t\">Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/28\" class=\"nounderline abstract_t\">Rhie S, Turcios R, Buckley H, Suh B. Clinical features and treatment of Malassezia folliculitis with fluconazole in orthotopic heart transplant recipients. J Heart Lung Transplant 2000; 19:215.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/29\" class=\"nounderline abstract_t\">Shparago NI, Bruno PP, Bennett J. Systemic Malassezia furfur infection in an adult receiving total parenteral nutrition. J Am Osteopath Assoc 1995; 95:375.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/30\" class=\"nounderline abstract_t\">Kolecka A, Khayhan K, Arabatzis M, et al. Efficient identification of Malassezia yeasts by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). Br J Dermatol 2014; 170:332.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/31\" class=\"nounderline abstract_t\">Vuran E, Karaarslan A, Karasartova D, et al. Identification of Malassezia species from pityriasis versicolor lesions with a new multiplex PCR method. Mycopathologia 2014; 177:41.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/32\" class=\"nounderline abstract_t\">Cornu M, Goudjil S, Kongolo G, et al. Evaluation of the (1,3)-&beta;-D-glucan assay for the diagnosis of neonatal invasive yeast infections. Med Mycol 2018; 56:78.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/33\" class=\"nounderline abstract_t\">Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2014; 20 Suppl 3:76.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/34\" class=\"nounderline abstract_t\">Leong C, Buttafuoco A, Glatz M, Bosshard PP. Antifungal Susceptibility Testing of Malassezia spp. with an Optimized Colorimetric Broth Microdilution Method. J Clin Microbiol 2017; 55:1883.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/35\" class=\"nounderline abstract_t\">Galvis-Mar&iacute;n JC, Rodr&iacute;guez-Bocanegra MX, Pulido-Villamar&iacute;n ADP, et al. [In vitro antifungal activity of azoles and amphotericin B against Malassezia furfur by the CLSI M27-A3 microdilution and Etest(&reg;) methods]. Rev Iberoam Micol 2017; 34:89.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/36\" class=\"nounderline abstract_t\">Rojas FD, C&oacute;rdoba SB, de Los &Aacute;ngeles Sosa M, et al. Antifungal susceptibility testing of Malassezia yeast: comparison of two different methodologies. Mycoses 2017; 60:104.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/37\" class=\"nounderline abstract_t\">Marcon MJ, Durrell DE, Powell DA, Buesching WJ. In vitro activity of systemic antifungal agents against Malassezia furfur. Antimicrob Agents Chemother 1987; 31:951.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/38\" class=\"nounderline abstract_t\">Sugita T, Tajima M, Ito T, et al. Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species. J Clin Microbiol 2005; 43:2824.</a></li><li><a href=\"https://www.uptodate.com/contents/invasive-malassezia-infections/abstract/39\" class=\"nounderline abstract_t\">Tragiannidis A, Bisping G, Koehler G, Groll AH. Minireview: Malassezia infections in immunocompromised patients. Mycoses 2010; 53:187.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2428 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MYCOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">EPIDEMIOLOGY</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Outbreaks</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL PRESENTATION</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">SUSCEPTIBILITY TESTING</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">TREATMENT</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">OUTCOME OF INFECTION</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2428|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/71053\" class=\"graphic graphic_picture\">- Malassezia furfur histology</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=candida-infections-of-the-bladder-and-kidneys\" class=\"medical medical_review\">Candida infections of the bladder and kidneys</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infectious-folliculitis\" class=\"medical medical_review\">Infectious folliculitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">Tinea versicolor (Pityriasis versicolor)</a></li></ul></div></div>","javascript":null}